Amy Shaw

Head of Process and Product Development at Takeda, USA

Speaker

Amy Shaw is the Head of Process and Product Development at Takeda Pharmaceuticals, where she heads a team leading the design and development of Takeda’s portfolio of allogenic cell therapy platforms. Amy has over 10 years of experience in Cell Therapies, she began her career contributing to key process improvements to the manufacturing process of Kymriah at Novartis. She was an early employee at Repertoire Immune Medicines, where she led the development of a novel autologous tumor-associated-antigen specific T cell process for phase I clinical trials. She later joined Beam Therapeutics, where she was responsible for the development of a novel allogenic CAR-T process using CRISPR-like gene editing techniques. After joining Takeda, Amy has been responsible for leading the process design for viral vectors and cell therapies in multiple programs, incorporating the development of small-scale models, process automation, digital data capture, and IND-enabling data packages.